



SAVING LIVES WITH AI AND SPECIALIZED MRI.

PROSTATID™

01 / **ADVANCED**


ProstatID™ is a software interface for post-processing MRI using cloud based computing, physician workstation integration, and AI image interpretation to provide highly accurate prostate cancer diagnostics.

02 / **ACCURATE**

ProstatID™ eliminates the visualization limitations of physicians using complex wholistic learning algorithms improving physician confidence and accuracy for precision diagnostics and cancer targeting for follow-up exams.

03 / **ACCESSIBLE**

ProstatID™ facilitates low cost prostate cancer screening by using affordable technology, delivering significant patient throughput improvements, and can lower physician and care-provider liability insurance premiums.



REQUEST INFO



MEET BOT IMAGE

OUR STORY

Bot Image™, Inc is a medical imaging software company that utilizes artificial intelligence technology for magnetic resonance imaging interpretation.

BotImage is a subsidiary of

OUR TECHNOLOGY

Bot Image's software interprets multi-parametric and bi-parametric MRI using random forest with instance weight and MR segmentation by deep learning with holistically nested

OUR VISION


Bot Image™, Inc will bring prostate cancer early detection with MRI and AI to the forefront of medicine with ProstatID™. Our highly advanced, non-invasive technology shows promise of

BotImage is a subsidiary of ScanMed®, LLC, an established medical device company specializing in MRI hardware, prostate cancer detection, and COPD functional lung imaging with the intent of bringing highly accurate MRI interpretation software to physicians.


learning with nonlocally-nested networks. Our first product, ProstatID™ utilizes proprietary MR image sets, radiologist interpretations, segmented prostate gland image sets, pathology laboratory results, correlation data, and first-pass AI interpretations to aid in the early diagnosis of prostate cancer.

technology shows promise of delivering high 90th percentile sensitivity in detection, as well as, specificity (accuracy) with the near elimination of false positives and false negatives. Once refined, we will then utilize the same baseline AI algorithms to address the early diagnosis of other cancers and COPD.

LEARN MORE



CONTACT US



REQUEST INFO

Please fill your contact details below:

NAME

EMAIL

SUBJECT

PHONE

ADDRESS

Submit

LINKS

Home
ProstatID

ABOUT

info@botimage.com
sales@botimage.com
Tel: 402-934-2650
Bot Image™

SOCIAL



[About](#)
[Contact](#)
[News](#)

bot image™
A division of ScanMed, LLC
9840 S 140th St, Ste 8
Omaha, NE 68138

© 2019 by BotImage, Inc., a subsidiary of ScanMed, LLC

